Profound signs Australia, NZ distribution deal

Executive Summary

• Profound Medical Corp. has entered into an exclusive distribution and supply agreement with Getz Healthcare to distribute its Tulsa-Pro system in Australia and New Zealand.
• The Tulsa-Pro system is an AI-powered, MR-guided robotic system for prostate therapy, offering a non-surgical alternative to radiation or surgery.
• Profound is expanding its commercial strategy by deploying a direct sales team in North America while leveraging strategic partners like Getz Healthcare for international markets, with plans to expand the partnership to other Asia Pacific regions.

Key Details

• Agreement Type: Exclusive distribution and supply agreement.
• Parties: Profound Medical Corp. (Licensor/Manufacturer) and Getz Healthcare (Distributor).
• Territory: Australia and New Zealand.
• Product: Tulsa-Pro system, described as the only AI-powered, MR-guided robotic system for prostate therapy.
• Technology Features: Uses robotically controlled, directional ultrasound to precisely ablate prostate tissue while protecting surrounding structures; enables real-time MRI thermography and autonomous temperature control.
• Strategic Expansion: Profound is actively pursuing opportunities to expand the strategic commercial partnership with Getz Healthcare to include additional key markets across Asia Pacific.
• Commercial Strategy: Profound is deploying its own direct sales team in North America while partnering with select strategic distribution partners for other global regions.
• Regulatory Status: Tulsa-Pro is CE marked, Health Canada approved, and 510(k) cleared by the U.S. FDA.

Notable Quotes

• Derek Foltin, Getz Healthcare ANZ Managing Director: "Our exclusive partnership with Profound Medical marks a significant step in advancing precision prostate care across Australia and New Zealand... The Tulsa-Pro system strengthens our commitment to deliver innovative, clinically proven technologies that improve patient outcomes and further advances our position in prostate cancer surgery and minimally invasive therapies."
• Arun Menawat, Profound Medical CEO and Chairman: "Like in many other regions around the globe, prostate cancer is the most commonly diagnosed cancer in men in Australasia... We are excited to gain access to this significant market for Tulsa-Pro. Beyond Australia and New Zealand, we are actively pursuing other potential opportunities to expand our strategic commercial partnership with Getz Healthcare to include additional key markets across Asia Pacific."